Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Elite Pharma Inc (OP: ELTP )

0.1315 +0.0023 (+1.78%)
Streaming Delayed Price Updated: 1:42 PM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Elite Pharma Inc

< Previous 1 2 Next >
Elite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 ended December 31, 2023 and Provides Conference Call Information
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2024 Financial Results on February 15, 2024
Via ACCESSWIRE
Elite Pharmaceuticals Files ANDA with US FDA to Market Central Nervous System Stimulant
Via ACCESSWIRE
Elite Pharmaceuticals Announces First Product Shipment of Generic Adderall XR(R) to Marketing Partner Prasco, LLC
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for Second Quarter of Fiscal Year 2024 ended September 30, 2023 and Provides Conference Call Information
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for First Quarter of Fiscal Year 2024 ended June 30, 2023 and Provides Conference Call Information
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2024 Financial Results on August 15, 2023
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2023 and Provides Conference Call Information
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2023 Financial Results on June 30, 2023
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2024 Financial Results on November 15, 2023
Via ACCESSWIRE
Elite Pharmaceuticals Files ANDA with US FDA to Market Opiate Analgesic Product
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. Appoints Carter Ward as Chief Financial Officer
Via ACCESSWIRE
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. Appoints Mark Pellegrino as Chief Financial Officer
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2023 ended December 31, 2022 and Provides Conference Call Information
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2023 Ended September 30, 2022 and Provides Conference Call Information
Via ACCESSWIRE
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2023 ended June 30, 2022, and Provides Conference Call Information
Via ACCESSWIRE
Elite Pharmaceuticals Files ANDA with US FDA to Market Antimetabolite Product
Via ACCESSWIRE
Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study
Via ACCESSWIRE
Elite Pharmaceuticals Files ANDA with US FDA to Market Dopamine Agonist
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2023 Financial Results on November 15, 2022
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2023 Financial Results on August 16, 2022
Via ACCESSWIRE
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2022 and Provides Conference Call Information
Conference Call Scheduled for Thursday, June 30 at 11:30 AM EDT 
From Elite Pharmaceuticals, Inc.
Via AccessWire
Elite Pharmaceuticals Receives FDA Approval for Generic Sabril(R)
NORTHVALE, NJ / ACCESSWIRE / June 29, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, today announced... 
From Elite Pharmaceuticals, Inc.
Via AccessWire
Exposures Product Safety
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2022 Financial Results on June 30, 2022
Financials for Fiscal Year 2022 Ended March 31, 2022 will be released on June 29, 2022 
From Elite Pharmaceuticals, Inc.
Via AccessWire
Exposures Product Safety
Elite Pharmaceuticals, Inc. Appoints Robert Chen as Chief Financial Officer
NORTHVALE, NJ / ACCESSWIRE / May 11, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing and manufacturing niche generic products,... 
From Elite Pharmaceuticals, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures Legal Regulatory
Elite Pharmaceuticals and Praxgen Pharmaceuticals Receive FDA Approval for Generic Doxycycline
NORTHVALE, NJ / ACCESSWIRE / April 4, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCQB:ELTP), a specialty pharmaceutical company developing niche generic products, today announced... 
From Elite Pharmaceuticals, Inc.
Via AccessWire
Exposures Product Safety
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year Ended December 31, 2021 and Provides Conference Call Information
Conference Call Scheduled for Tuesday, February 15 at 11:30 AM EST NORTHVALE, NJ / ACCESSWIRE / February 14, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company")(OTCQB:ELTP), a specialty... 
From Elite Pharmaceuticals, Inc.
Via AccessWire
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2022 Financial Results on February 15, 2022
Financials for Third Quarter Fiscal Year 2022 Ended December 31, 2021 will be released February 14, 2022 NORTHVALE, NJ / ACCESSWIRE / February 9, 2022 / Elite Pharmaceuticals, Inc. ("Elite" or the... 
From Elite Pharmaceuticals, Inc.
Via AccessWire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.